India Glycols Limited has announced a board meeting scheduled for March 17, 2026, to deliberate on the declaration of interim dividend for the financial year 2025-26. The company has formally notified both BSE and NSE about this upcoming board meeting in compliance with regulatory requirements.

Board Meeting Details

The board meeting has been convened pursuant to Regulation 29 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting will specifically consider the declaration of interim dividend, if any, for the current financial year.

Trading Window Closure

In accordance with the company's Code of Conduct for Regulating, Monitoring and Reporting Trading in Securities, India Glycols has announced a temporary closure of the trading window. This measure ensures compliance with insider trading regulations during the period leading up to and following the board meeting.

Corporate Communication

The official notification was issued on March 10, 2026, and has been communicated to both major stock exchanges where the company's shares are listed. The announcement was signed by Ankur Jain, Head (Legal) & Company Secretary, and the information has been made available on the company's official website at www.indiaglycols.com for stakeholder reference.

Company Operations

India Glycols Limited operates from multiple locations with its registered office in Kashipur, Uttarakhand, and corporate office in Kolkata, West Bengal. The company maintains additional operational facilities in NOIDA, Uttar Pradesh, reflecting its pan-India presence in the chemicals and allied products sector.

India Glycols Limited has announced the rescheduling of crucial National Company Law Tribunal (NCLT) ordered meetings related to its Scheme of Arrangement. The meetings, originally scheduled for March 9, 2026, have been moved to March 24, 2026, following approval from the NCLT Allahabad Bench at Prayagraj.

Meeting Rescheduling Details

The company filed an interim application seeking rescheduling due to the unavailability of the Hon'ble Chairperson appointed by the NCLT to chair the meetings on March 9, 2026. The NCLT, through its revised order dated February 16, 2026, granted permission for the meetings to be convened on the new date.

Scheme of Arrangement Background

The meetings are being conducted for the purpose of considering and approving the Scheme of Arrangement under Sections 230 to 232 of the Companies Act, 2013. The scheme involves three entities and their respective shareholders:

• India Glycols Limited (Applicant No. 1/Demerged Company)
• Ennature Biopharma Limited
• IGL Spirits Limited

Meeting Participants and Process

The NCLT has directed the convening of separate meetings for two distinct groups of stakeholders. Both meetings will be conducted through video conferencing to ensure broader participation and accessibility.

Regulatory Compliance and Documentation

The disclosure was made under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has made the NCLT order available on its website for stakeholder reference. The communication was addressed to both BSE Limited (Scrip Code: 500201) and National Stock Exchange of India Limited (Symbol: INDIAGLYCO).

The company noted that a certified copy of the order is awaited, and the Scheme remains subject to applicable regulatory and other approvals. This rescheduling represents a procedural adjustment to accommodate the chairperson's availability while maintaining the integrity of the approval process for the proposed corporate restructuring.